Ophthalmic panel tackles Prelex technique
This article was originally published in The Gray Sheet
Executive Summary
Study criteria for intraocular lenses to correct presbyopia following clear lens extraction will be explored March 5 by FDA's Ophthalmic Devices Panel in Gaithersburg, Md. Potential candidates for a presbyopic lens exchange (Prelex) indication include Advanced Medical Optics' Array multifocal lens, Eyeonics' CrystaLens AT-45 and Alcon's Acrysof multifocal IOL. Array has been available for U.S. use in cataract surgery since 1997, while AT-45 earned approval Nov. 14 for aphakic treatment of near, immediate and distance vision (1"The Gray Sheet" Dec. 22, 2003, p. 25)...
You may also be interested in...
CrystaLens Accommodating IOL First To Market; Firm Eyes Expanded Labeling
Eyeonics, Inc. will file a supplemental PMA for its CrystaLens AT-45 accommodating posterior chamber intraocular lens to broaden the treatment range beyond 1.0 diopter
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.